2. Artificial Organs (ESAO) as a board member. In
2006, he was elected to the Executive Board of
ESAO as a Treasurer of this society. He was member
of the ProTem Group (2003–2005), working group
for the European Alliance in the field of biomedical
engineering, then he was elected to be a member of
the Interim Executive Board of the newborn Euro-
pean society (2005–2006)—European Alliance for
Medical Biological Engineering and Sciences
(EAMBES)—and in 2006 he was a member of the
EAMBES Council.
In 2006, he was elected to the Administrative
Council of the International Federation of Medical
and Biological Engineering (IFMBE—120 000
members). Since 2009, he has been a fellow of the
American Institute of Medical and Biological
Engineering.
During the last 10 years, he has been engaged in
the organization of several international scientific
meetings as:
• Member of the 14-person planning committee of
the Diabetes Technology Meeting in 2005 (San
Francisco), 2006 (Atlanta), 2007 (San Francisco),
2008 (Bethesda), 2009 (San Francisco), and 2010
(Bethesda);
• Cochairman of the Artificial Organs Track on the
World Congress “Medical Physics and Biomedical
Engineering,” Seoul 2006;
• President of the XXXI Congress European Society
of Artificial Organs 2004;
• Chairman of the Local Organizing Committee of
the XXIII Congress European Society of Artificial
Organs, 1996;
• Cochairman of the 14th seminars organized in the
frame of the International Center of Biocybernet-
ics and Biomedical Engineering PolishAcademy of
Sciences, 2002–2010.
He has been an author and coauthor of 294 publi-
cations including monographs, chapters, articles, and
conferences materials, as well as 14 Polish and inter-
national patents and 27 expert reports. The most
important results of his work were published in
the following journals: Hormone and Metabolic
Research, Journal of Membrane Science, Artificial
Organs, International Journal of Artificial Organs,
Diabetes Technology & Therapeutics, and Journal of
Telemedicine and Telecare, Annals of Biomedical
Engineering.
In general, Dr. Wojicki’s research activity can be
divided into three blocks: the first, related to techni-
cal support of the diabetes treatment; the second,
dealing with membrane techniques and their applica-
tions in extracorporeal blood purification; and the
third, which gathers all other projects related to tech-
nical support of the intensive therapies applied for
chronic diseases. The research conducted in his
laboratory (Biomedical Engineering Methods for
Support of Intensive Therapies) concerning the
development of new methods for technical support in
therapy of diabetes was started in the late 1970s. The
most interesting results of these works include the
following:
• development of the first Polish prototype of the
portable insulin pump in 1979;
• development of a system for monitoring the opera-
tion of the infusion micropump system (EU and
US patents—1991);
• development of original indices for assessment of
glycemia control: “J” index—concerning the
description of the glycemia control; the set of
indices “DBGHIGH,” “DBGLOW” describing the
control of glycemia based on continuous 24 hours
of measurement of the glucose concentration;
• development of and implementation of home tele-
care system TeleDiaPreT for long-term monitoring
of diabetes therapy by multiple insulin injections in
pregnant type 1 diabetic patients;
• development of the computerized system for mea-
surement of tissue glucose utilization in humans
(TISS), patented and implemented in four clinics
in Poland;
• development and implementation of the short-
term mobile telecare system TeleMed for monitor-
ing in real time of intensive diabetes therapy by
multiple insulin injections technique in patients
with newly diagnosed type 1 diabetes;
• development of the telematic system for early
detection and monitoring of progress of diabetic
retinopathy (joint work conducted with the Nara
Institute of Science and Technology, Nara, Japan);
• design and development of the TeleDiaFos home
telecare system aimed at monitoring of the treat-
ment of patients with diabetic foot syndrome;
• application of microdialysis technique to establish
the course of changes in a number of biochemical
parameters, characterizing the metabolic condition
of the patient in different types of acute diabetic
complications;
• development of a hemoglobin glycation process
model to evaluate the relationship between glyce-
mia courses and hemoglobin A1c—the basic
marker of the glycemic control over long periods
of time.
The greatest part of the presented projects earlier
was realized by Dr.Wojcicki’s team together with his
medical partners of the Clinic of Gastroenterology
EDITORIAL914
Artif Organs, Vol. 35, No. 10, 2011
3. and Metabolic Diseases headed by Prof.W. Karnafel.
The results of the research work of Dr. Wojcicki’s
team in the field of technical support of diabetes
treatment are well recognized in the world due to
their innovative aspects as well as the long lasting
international cooperation with many worldwide
experts in the field of artificial pancreas and diabetes
treatment.
It is truly my pleasure to welcome Dr. Wojcicki as
coeditor of Eastern Europe.As this region’s coeditor,
he will provide the Editorial Board his counsel on the
operations of Artificial Organs and promote artificial
organ technologies in his region and support our
mission of fostering communications among all of
our constituents including scientists, clinicians, indus-
try, and patients.
Paul S. Malchesky, DEng
Editor-in-Chief
10 W. Erie St. Suite 200
Painesville, OH 44077, USA
E-mail: artiforgs@aol.com
EDITORIAL 915
Artif Organs, Vol. 35, No. 10, 2011
4. Copyright of Artificial Organs is the property of Wiley-Blackwell and its content may not be copied or emailed
to multiple sites or posted to a listserv without the copyright holder's express written permission. However,
users may print, download, or email articles for individual use.
